By creating living medicines with smart components designed to address the underlying drivers of disease, this clinical-stage Boston biotech company is transforming treatment paradigms.
Founded in 2014, Synlogic is focused on a new therapeutic modality known as Synthetic Biotic medicines. [Synlogic]
Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including phenylketonuria (PKU) and enteric hyperoxaluria (HOX). The company is also building a portfolio of assets suitable for partnering in immunology and oncology . . .
![Study will evaluate firm’s retinal pigment cell therapy in Stargardt disease.[krishnacreations - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Sept22_2011_22415259_ColorfulEyeball_StemCellTherapyBlindness6329668463-2-218x150.jpg "Using AI to Assess Eye Scans, Scientists Find “Retinal Age Gap” Predicts Mortality Risk")
